A nearly 3 years follow-up suggested a 16.9-months median PFS of the treatment of triplet combination and 10.7-months of the treatment with dabrafenib and trametinib.622 Combination of an investigational PD-1 antibody, spartalizumab, dabrafenib and trametinib leads to an ORR of 78% in advanced BRAF-mutant melanoma, including 44% complete response, which suggests the triplet combinatorial regimen is promising, although in a relatively small population.623 With the successful trials of combined targeted therapies and ICBs, numerous studies of combinatorial therapies begin to emerge. This evidence concerns the gene BRAF and melanoma.